AVITA Medical (NASDAQ: RCEL) has reported a notable advance in wound care, with new interim data showing its Cohealyx dermal matrix dramatically accelerates the path to skin grafting. Specifically, results from the ongoing Cohealyx-I multi-center study indicate that the product reduces the average time to grafting from 33.2 days to just 13.6 days—a nearly 20-day improvement for patients with full-thickness wounds.
The company announced the findings Monday from Valencia, California. Importantly, the results met the threshold for statistical superiority (p<0.001) when compared to a literature-based benchmark derived from a meta-analysis of approximately 900 patients treated with leading dermal matrices.
Looking more closely at the data, the interim analysis included 40 patients. The median time to grafting reached 11 days, while some patients underwent grafting as early as five days after treatment. In fact, 25% of patients received grafts within one week, and 72% did so within two weeks. At the same time, investigators reported a 90% satisfaction rate at the time of grafting—even among surgeons using the product for the first time.
Why Speed Matters Clinically
Surgeons emphasize that faster wound bed preparation can significantly impact patient outcomes. Derek Bell, MD—Professor of Plastic Surgery and Kessler Burn Director at the University of Rochester Medical Center—highlighted this point directly.
“Preparing the wound bed efficiently remains one of the key challenges in managing full-thickness wounds,” Bell said. “These interim results show that Cohealyx supports vascularization and enables earlier grafting, which is central to improving patient outcomes. Notably, we observed these results across a wide range of complex wounds.”
That consistency stands out. Because full-thickness wounds vary widely in cause and severity, demonstrating reliable performance across diverse cases strengthens the argument for broader clinical adoption.
Strengthening AVITA’s Strategy
At the same time, AVITA leadership views these results as validation of its broader wound care strategy. Interim CEO Cary Vance underscored the significance of the findings.
“This data reinforces our belief that Cohealyx can establish a new benchmark in wound bed preparation,” Vance said. “The meaningful reduction in time to grafting, combined with high investigator satisfaction, highlights its potential as a differentiated solution.”
Moreover, Cohealyx complements AVITA’s existing portfolio. The product fits alongside RECELL, the company’s FDA-approved Spray-On Skin technology. Together, these therapies address sequential stages of healing—first preparing the wound bed with a dermal matrix, then enabling autologous skin regeneration.
What Comes Next
AVITA plans to release the full Cohealyx-I dataset later in 2026. Researchers will continue to follow patients for roughly six months after grafting to evaluate durability and monitor safety outcomes.
In the near term, however, the company will spotlight these interim findings at an American Burn Association symposium on April 15. The session will feature Dr. Bell and Dr. Jonathan Schoen of LSUHSC. Additionally, AVITA will host a KOL webinar on April 16 at 4:30 p.m. ET, where Dr. Bell and Dr. Lourdes Castañón of the University of Arizona will present detailed data and case studies.
The study remains registered on ClinicalTrials.gov under NCT06787690.
About AVITA Medical
AVITA Medical focuses on developing therapies for acute wound care. Its technologies aim to accelerate healing and improve recovery times. At the center of its platform is RECELL®, which uses a patient’s own skin to create Spray-On Skin™ for treating burn and trauma wounds.
In the U.S., the company also holds exclusive rights to Cohealyx, a collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix—further expanding its reach across the wound healing continuum.
The post AVITA Medical’s Cohealyx Slashes Time to Skin Grafting by Nearly 20 Days in Interim Study appeared first on PRISM MarketView.